Analyst firms · Citigroup · RMD
Citigroup RMD price target and rating history
ResMed Inc. (RMD) · Health Care
Citigroup rates ResMed Inc. (RMD) Neutral with a $235 price target, as of its latest action on Jul 13, 2026. It has published 8 rating actions on RMD since June 2021, including 2 upgrades and 5 downgrades. Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Citigroup's target matches it.
- Current rating
- Neutral
- Price target
- $235
- Median target, all firms
- $235
- Actions on RMD
- 8
Citigroup price target on RMD
Every Citigroup rating on RMD
- Jul 13, 2026
- Sep 18, 2025
- Jun 24, 2024
- Oct 28, 2022
- Sep 8, 2022
- Aug 12, 2022
- Jan 31, 2022
- Jun 28, 2021
How other firms rate RMD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | Nov 2, 2026 | |
| RBC Capital Markets | Outperform | $262 | Sep 15, 2026 |
| Rothschild & Co Redburn | Neutral | $230 | Aug 19, 2026 |
| Citigroup | Neutral | $235 | Jul 13, 2026 |
| Morgan Stanley | Equal-Weight | $230 | Jun 17, 2026 |
| Robert W. Baird | Neutral | $275 | Dec 16, 2025 |
Questions about Citigroup and RMD
- What is Citigroup's price target for RMD?
- Citigroup's latest stated price target for ResMed Inc. (RMD) is $235, from its action on Jul 13, 2026.
- What is Citigroup's rating on RMD?
- Citigroup rates RMD Neutral, a neutral rating, as of Jul 13, 2026.
- When did Citigroup last change its view on RMD?
- On Jul 13, 2026, Citigroup downgrades to Neutral from Buy, price target $235.
- How does Citigroup's RMD target compare with other analysts?
- Across 5 firms with a RMD price target in the last 12 months, the median target is $235. Citigroup's target matches it.
More RMD rating histories
- RBC Capital Markets13
- Morgan Stanley4
- Robert W. Baird4
- CLSA5
- Wolfe Research3
- Needham3
- J.P. Morgan6
- BofA Securities3
All Citigroup ratingsRMD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.